This is an old revision of this page, as edited by Innerstream (talk | contribs) at 13:50, 24 December 2024. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 13:50, 24 December 2024 by Innerstream (talk | contribs)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Identifiers | |
|---|---|
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H19N3OS |
| Molar mass | 289.40 g·mol |
| 3D model (JSmol) | |
SMILES
| |
Butamisole is a pharmaceutical drug used in veterinary medicine. It is an anthelmintic of the imidazothiazole class. In dogs it is used for the treatment of infections with whipworms such as Trichuris vulpis and with hookworm such as Ancylostoma caninum. It acts as a nicotinic acetylcholine receptor agonist that causes sustained muscle contraction in the parasite followed by depolarizing neuromuscular blockade which leads to paralysis.
References
- B. T. Alford, G. T. Wang, T. R. Garces, R. B. Dougherty, R. E. Bradley (1979). "The efficacy and safety of injectable butamisole in dogs". Veterinary Medicine & Small Animal Clinician. 74 (4): 487–495.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Martin, R.J. (1997). "Modes of action of anthelmintic drugs". The Veterinary Journal. 154 (1): 11–34. doi:10.1016/S1090-0233(05)80005-X. PMID 9265850.
- ^ "Butamisole". Inxight Drugs. National Center for Advancing Translational Sciences.
 | This veterinary medicine–related article is a stub. You can help Misplaced Pages by expanding it. |